130 related articles for article (PubMed ID: 9096658)
1. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations.
Haupt R; Fears TR; Heise A; Gadner H; Loiacono G; De Terlizzi M; Tucker MA
Int J Cancer; 1997 Mar; 71(1):9-13. PubMed ID: 9096658
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis.
Haupt R; Fears TR; Rosso P; Colella R; Loiacono G; de Terlizzi M; Mancini A; Comelli A; Indolfi P; Donfrancesco A
Pediatr Hematol Oncol; 1994; 11(5):499-507. PubMed ID: 7826846
[TBL] [Abstract][Full Text] [Related]
3. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis.
Horibe K; Matsushita T; Numata S; Miyajima Y; Katayama I; Kitabayashi T; Yanai M; Sekiguchi N; Egi S
Cancer; 1993 Dec; 72(12):3723-6. PubMed ID: 8252489
[TBL] [Abstract][Full Text] [Related]
4. Acute leukemia in association with Langerhans cell histiocytosis.
Egeler RM; Neglia JP; Aricò M; Favara BE; Heitger A; Nesbit ME
Med Pediatr Oncol; 1994; 23(2):81-5. PubMed ID: 8202046
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans' cell histiocytosis.
López-Andreu JA; Ferris J; Verdeguer A; Esquembre C; Castel V
Cancer; 1994 Sep; 74(5):1650-2. PubMed ID: 7864932
[No Abstract] [Full Text] [Related]
6. Acute myeloid leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis of bone.
Haupt R; Comelli A; Rosanda C; Sessarego M; De Bernardi B
Am J Pediatr Hematol Oncol; 1993 May; 15(2):255-7. PubMed ID: 8498650
[TBL] [Abstract][Full Text] [Related]
7. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma.
Sugita K; Furukawa T; Tsuchida M; Okawa Y; Nakazawa S; Akatsuka J; Ohira M; Nishimura K
Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):99-104. PubMed ID: 8447565
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis.
Matsuzaki A; Inamitsu T; Watanabe T; Ohga S; Ishii E; Nagotoshi Y; Tasaka H; Suda M; Ueda K
Br J Haematol; 1994 Apr; 86(4):887-9. PubMed ID: 7918090
[TBL] [Abstract][Full Text] [Related]
9. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH).
Lopes LF; de Camargo B
Med Pediatr Oncol; 1999 Apr; 32(4):315. PubMed ID: 10102032
[No Abstract] [Full Text] [Related]
10. Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis.
Kager L; Heise A; Minkov M; Möbius D; Kotte W; Schulte-Overberg U; Henze G; Gadner H
Pediatr Hematol Oncol; 1999; 16(3):251-6. PubMed ID: 10326224
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis and acute leukemia: unusual association in two cases.
Aricò M; Comelli A; Bossi G; Raiteri E; Piombo M; Egeler RM
Med Pediatr Oncol; 1993; 21(4):271-3. PubMed ID: 8469222
[TBL] [Abstract][Full Text] [Related]
12. VP-16 and the treatment of histiocytosis.
Gadner H; Ladisch S; Aricó M; Broadbent V; Jakobson A; Komp D; Nicholson S
Eur J Pediatr; 1994 May; 153(5):389. PubMed ID: 8033933
[No Abstract] [Full Text] [Related]
13. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.
Ladisch S; Gadner H; Aricò M; Broadbent V; Grois N; Jacobson A; Komp D; Nicholson HS
Med Pediatr Oncol; 1994; 23(2):107-10. PubMed ID: 8202031
[TBL] [Abstract][Full Text] [Related]
14. Etoposide-related acute promyelocytic leukemia.
Kudo K; Yoshida H; Kiyoi H; Numata S; Horibe K; Naoe T
Leukemia; 1998 Aug; 12(8):1171-5. PubMed ID: 9697869
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis.
Egeler RM
Cancer; 1995 Jan; 75(1):134-6. PubMed ID: 7804969
[No Abstract] [Full Text] [Related]
16. Etoposide in recurrent childhood Langerhans' cell histiocytosis: an Italian cooperative study.
Ceci A; de Terlizzi M; Colella R; Balducci D; Toma MG; Zurlo MG; Macchia P; Mancini A; Indolfi P; Locurto M
Cancer; 1988 Dec; 62(12):2528-31. PubMed ID: 3056605
[TBL] [Abstract][Full Text] [Related]
17. Langerhans cell histiocytosis and etoposide: risks vs. benefits.
D'Angio GJ
Med Pediatr Oncol; 1994; 23(2):69-71. PubMed ID: 8202044
[No Abstract] [Full Text] [Related]
18. Secondary acute myelogenous leukemia following safe exposure to etoposide.
Stine KC; Saylors RL; Sawyer JR; Becton DL
J Clin Oncol; 1997 Apr; 15(4):1583-6. PubMed ID: 9193356
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
[TBL] [Abstract][Full Text] [Related]
20. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH
J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
